StageZero Life Sciences Ltd.

Equities

SZLS

CA8525403017

Biotechnology & Medical Research

Market Closed - Toronto S.E. 11:00:00 2024-04-16 am EDT 5-day change 1st Jan Change
0.04 CAD -.--% Intraday chart for StageZero Life Sciences Ltd. -.--% -11.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Focus Turns to -2- DJ
North American Morning Briefing : All Eyes on -2- DJ
Transcript : StageZero Life Sciences Ltd., Q3 2023 Earnings Call, Nov 15, 2023
StageZero Life Sciences Ltd. Partners with My One Medical Source and 1,000+ Medical Access Points in the USA CI
StageZero Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer Offerings CI
StageZero Life Sciences MT
Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer Offerings CI
North American Morning Briefing : Stock Futures -2- DJ
Transcript : StageZero Life Sciences Ltd., Q2 2023 Earnings Call, Aug 15, 2023
StageZero Life Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : StageZero Life Sciences Ltd. - Shareholder/Analyst Call
Transcript : StageZero Life Sciences Ltd., Q1 2023 Earnings Call, May 16, 2023
North American Morning Briefing : Retail Sales, -2- DJ
StageZero Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : StageZero Life Sciences Ltd., Q4 2022 Earnings Call, Apr 03, 2023
StageZero Life Sciences Ltd. Auditor Raises 'Going Concern' Doubt CI
StageZero Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
StageZero Life Sciences Says Secured C$25 Million Capital Commitment from GEM Global Yield LLC SCS MT
StageZero Life Sciences Brief: Says Secured C$25 Million Capital Commitment from GEM Global Yield LLC SCS MT
Transcript : StageZero Life Sciences Ltd., Q3 2022 Earnings Call, Nov 15, 2022
North American Morning Briefing : Positive China -2- DJ
StageZero Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
StageZero Life Sciences Ltd. announced that it has received CAD 0.177 million in funding CI
Chart StageZero Life Sciences Ltd.
More charts
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.
More about the company